Author

R. Bueno

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Research Focus:cell type annotation· 4 Assay:bulk RNA-seq· 2 Assay:CRISPR screen· 2 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

C. J. Ye· 2 shared J. Eyquem· 2 shared Y. Sun· 2 shared A. Arkal· 1 shared A. Byford· 1 shared A. Byrne· 1 shared A. Gervais· 1 shared A. J. Combes· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

C. J. Ye

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A cellular and spatial atlas of TP53-associated tissue remodeling in lung adenocarcinoma

W. Zhao, B. Kepecs, N. R. Mahadevan, A. Segerstolpe, J. L. Weirather, N. R. Besson, B. Giotti, B. Y. Soong, C. Li, S. Vigneau, M. Slyper, I. Wakiro, J. Jane-Valbuena, O. Ashenberg, A. Rotem, , A. M. Tsankov

This study constructs a multi-omic atlas of TP53-mutant lung adenocarcinoma tumors, revealing altered cellular identity, gene expression programs, and spatial interactions in the tumor microenvironment.

bioRxiv · Jun 28, 2023 · PreprintCancer Biology

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

C. A. Tsuchida, N. Brandes, R. Bueno, M. Trinidad, T. Mazumder, B. Yu, B. Hwang, C. Chang, J. Liu, Y. Sun, C. R. Hopkins, K. R. Parker, Y. Qi, A. Satpathy, E. Stadtmauer, , J. A. Doudna

This study investigates chromosome loss in CRISPR-Cas9-engineered T cells and shows a modified manufacturing process reduces it while preserving editing efficacy.

bioRxiv · Mar 22, 2023Cell Biology

Modular Pooled Discovery of Synthetic Knockin Sequences to Program Durable Cell Therapies

F. Blaeschke, Y. Y. Chen, R. Apathy, Z. Li, C. T. Mowery, W. A. Nyberg, A. To, R. Yu, R. Bueno, M. C. Kim, R. Schmidt, D. B. Goodman, T. Feuchtinger, J. Eyquem, C. J. Ye, , A. Marson

The paper develops ModPoKI, a platform for modular construction of DNA knockin libraries to identify gene constructs that enhance T cell function and persistence.

bioRxiv · Jul 27, 2022Immunology

Antibodies to ILT3 abrogate myeloid immunosuppression and enable tumor killing

P. E. Brandish, A. Palmieri, G. Ayanoglu, J. Baker, R. Bueno, A. Byford, M. Caniga, C. Chappell, H. Cherwinski, D. J. Cua, X. Du, L. Fayadat-Dilman, B. E. Hall, H. Issafras, B. Joyce-Shaikh, , J. Zhang-Hoover

This study shows anti-ILT3 antibodies block myeloid immunosuppression and enhance tumor killing in solid tumors.

bioRxiv · Dec 18, 2021 · PreprintCancer Biology

Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19

M. G. P. van der Wijst, S. E. Vazquez, G. C. Hartoularos, P. Bastard, T. Grant, R. Bueno, D. S. Lee, J. R. Greenland, Y. Sun, R. Perez, A. Ogorodnikov, A. Ward, S. A. Mann, K. L. Lynch, C. Yun, , C. R. Langelier

The paper examines IFN-I autoantibodies in critical COVID-19 patients through longitudinal single-cell analysis, revealing suppressed ISG-I responses in myeloid cells.

bioRxiv · Mar 9, 2021 · PreprintImmunology